Skip to main content

Defining and Evaluating In-Home Drug Disposal Systems for Opioid Analgesics

Completed

This public workshop provided an opportunity for stakeholders to examine the current use of in-home drug disposal systems with a focus on removing unused opioid analgesics from the home.

FDA issued a request for information associated with this workshop, comments can be found at the Federal Register.

Description

A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize a public workshop on the development and use of in-home drug disposal systems with a focus on removing unused opioid analgesics from the home.
The public workshop will feature invited presentations and discussions to:

  • Explore the types of in-home drug disposal options, other than mail back envelopes, that could be used to remove unused opioid analgesics from the home.
  • Examine the current landscape of laws and regulations that apply to in-home opioid disposal systems.
  • Discuss scientific, behavioral, health equity, and policy considerations for assessing the safety, use, and effectiveness of in-home opioid disposal systems, including the following questions:

- What is known/unknown about the methods (e.g., sequestration, adsorption, absorption) used in in-home disposal systems for rendering opioids unavailable for nonmedical use, assuming the product is used as intended?
- What approaches/methodologies are needed to evaluate the safe and correct use of in-home opioid disposal systems in real-world settings?
- How could person-centered design inform the development and use of in-home opioid disposal systems?

  • Consider potential strategies for encouraging and assessing the development and use of in-home opioid disposal systems that support the public health goal of mitigating the risk of nonmedical use or overdose associated with opioids.

The planning committee will organize the workshop, develop the agenda, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Collaborators

Committee

Elizabeth McGinty

Co-Chair

Alastair J. Wood

Co-Chair

Mark C. Bicket

Member

Irene Z. Chan

Member

Ruchi Fitzgerald

Member

Lewis Grossman

Member

Stephen Hoag

Member

Kathy McNamara

Member

Robert Morones

Member

Tom Prisinzano

Member

Thabet Tolaymat

Member

Jessica Young

Member

Patricia Zettler

Member

Carolyn Shore

Staff Officer

Sponsors

Amgen Inc

Association of American Medical Colleges

AstraZeneca

Biogen

Burroughs Wellcome Fund

Critical Path Institute

Eli Lilly and Company

FasterCures, Milken Institute

Foundation for the National Institutes of Health

Friends of Cancer Research

Johnson & Johnson

Medable

Merck & Co., Inc.

National Cancer Institute

National Center for Advancing Translational Sciences

National Institute of Allergy and Infectious Diseases

National Institute of Mental Health

National Institute of Neurological Disorders and Stroke

New England Journal of Medicine

Office of the Director (National Institutes of Health)

Sanofi

Takeda

U.S. Food and Drug Administration

Staff

Carolyn Shore

Lead

Noah Ontjes

Melvin Joppy

Kyle Cavagnini

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.